ImmutepASX:IMM -5.88% Gross Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 737 Biotechnology companies, Immutep ranks worse than 135685.07% on this metric.
The historical rank and industry rank for Immutep's Gross Margin % or its related term are showing as below:
ASX:IMM's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.92 * Ranked among companies with meaningful Gross Margin % only.
Immutep had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Immutep was 0.00% per year.
Immutep (ASX:IMM) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Immutep had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Immutep Gross Margin % Related Terms
Immutep Gross Margin % Historical Data
* Premium members only.
The historical data trend for Immutep's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IMM vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Immutep's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immutep Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immutep's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Immutep's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Immutep (ASX:IMM) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Immutep and its competitors. According to the industry distribution chart, Immutep ranks #999999 out of 737 companies in the Biotechnology industry.
Is Immutep's Gross Margin % too high?
Immutep's current Gross Margin % is 0.00%. Based on the distribution chart, Immutep ranks #999999 out of 737 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Immutep's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immutep ranks #999999 out of 737 companies for Gross Margin %. This places Immutep in the lower half of its industry. The industry median Gross Margin % is 60.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Immutep and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immutep's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (ASX:IMM) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Immutep (ASX:IMM), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMM has been successfully added to your 